Cite
Herbreteau G, Vallée A, Knol AC, et al. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget. 2018;9(38):25265-25276doi: 10.18632/oncotarget.25404.
Herbreteau, G., Vallée, A., Knol, A. C., Théoleyre, S., Quéreux, G., Varey, E., Khammari, A., Dréno, B., & Denis, M. G. (2018). Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget, 9(38), 25265-25276. https://doi.org/10.18632/oncotarget.25404
Herbreteau, Guillaume, et al. "Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy." Oncotarget vol. 9,38 (2018): 25265-25276. doi: https://doi.org/10.18632/oncotarget.25404
Herbreteau G, Vallée A, Knol AC, Théoleyre S, Quéreux G, Varey E, Khammari A, Dréno B, Denis MG. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget. 2018 May 18;9(38):25265-25276. doi: 10.18632/oncotarget.25404. eCollection 2018 May 18. PMID: 29861869; PMCID: PMC5982743.
Copy
Download .nbib